The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 339:406 August 6, 1998 Number 6
NextNext

Effect of Troglitazone in Type 2 Diabetes Mellitus

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
To the Editor: Close inspection of Figure 1 and Figure 2 in the article by Schwartz et al. (March 26 issue)1 suggests that the effects of troglitazone may have been waning when the study ended at 26 weeks, because the values for both glycosylated hemoglobin and fasting serum glucose in the patients given 600 mg of troglitazone daily were slightly higher than earlier. Did any of the patients continue to take troglitazone, and if so, what were its effects?


David M. Gorson, M.D.
Albany Medical Center
Albany, NY 12208

References

  1. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998;338:861-866. [Free Full Text]
 
To the Editor: Schwartz et al. found that glycosylated hemoglobin values, . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.